Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication

NCT05103332 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT05103332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05103332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication
Lead sponsor
Alnylam Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 5, 2021
Completion date
September 13, 2024
Enrollment
663 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension